Martin Perry, MBChB, BSc, MMEd, FRCP, clinical medical director for the National Health Service in Greater Glasgow and Clyde, Scotland, explains frontline care with biosimilars during COVID-19.
The Center for Biosimilars® spoke with Martin Perry, MBChB, BSc, MMEd, FRCP, Clinical Medical Director for the National Health Service (NHS) in the Greater Glasgow and Clyde region of Scotland about biosimilar savings and access during COVID-19. Perry was a presenter on the topic during the recent Terrapinn Festival of Biologics meeting in Basel, Switzerland.
Perry oversaw a COVID-19 ward and during this talk with The Center for Biosimilars® Senior Editor Tony Hagen, he explains the challenges of providing treatment for patients. He also sheds light on the United Kingdom's unique system of biosimilar choice and pricing. Access to biosimilars has broadened in the United Kingdom, partly due to the lower cost of these agents; but overall spending on biologics and specialty drugs is on the increase there, as in the United States.
Perry also addresses switching patients from reference products to biosimilars and patient acceptance. Nocebo, or the potential for patients with poor attitudes toward biosimilars to influence their own outcomes, is a very real concern, Perry explains, underscoring the need for strong educational efforts to support biosimilar use.
Brexit, or the United Kingdom's separation from the economic apron strings of the European Union, is well along since the beginning of 2021, and this has resulted in "no notable difference" in biosimilar supply, Perry reports.
The UK continues to get a handle on the COVID-19 pandemic, and its most recent spike in cases is on the wane; and in the Glasgow/Clyde area the infection rate hasn't been as serious as in the Southeast (London), partly because residents have been more adherent to mask mandates, Perry speculates. Overall, the United Kingdom has seen 1 in 7 residents infected with COVID-19, according to an ongoing New York Times analysis.
Perry says many UK residents are now coping with lingering complications of COVID-19, and the NHS is working to address these issues while seeking to reestablish normal services across the health care spectrum. "Currently, we're in a quieter phase in comparison with other stages" of the pandemic, he says.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).
Biosimilars Regulatory Roundup for September 2023—Podcast Edition
October 1st 2023On this episode, we discuss several regulatory updates from around the globe, including some European and Japanese approvals, the FDA’s 2-day workshop on the present science behind clinical efficacy testing for biosimilars, and streamlining biosimilar development.
Study: Biosimilar Use, Dose Rounding Produce More Cost Savings Than Either Strategy Alone
November 18th 2023A retrospective study of New England patients receiving trastuzumab or bevacizumab found that combining dose rounding and biosimilar use resulted in greater cost savings than either strategy alone.
Part 3: Study Questions Usefulness of Clinical Efficacy Trials for Oncology Biosimilars in Europe
November 16th 2023In part 3 of a 3-part series for Global Biosimilars Week, The Center for Biosimilars® reviews an analysis investigating whether clinical efficacy studies have an impact on prescribing decisions for oncology biosimilars across Europe.